Selective Laser Trabeculoplasty versus Argon Laser Trabeculoplasty in Glaucoma Patients Treated Previously with 360° Selective Laser Trabeculoplasty

Hutnik, Cindy; Crichton, Andrew; Ford, Bryce; Nicolela, Marcelo T.; Shuba, Lesya M.; Birt, Catherine M.; Sogbesan, Enitan; Damji, Karim F.; Dorey, Michael W.; Saheb, Hady; Klar, Neil; Guo, Hui; Hodge, William

doi:10.1016/j.ophtha.2018.09.037

Cited by 32 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of laser treatment for glaucoma is known to diminish over time, with anywhere between one-fifth and one-third of patients requiring at least one additional glaucoma medication in the 12 months following laser treatment [39][40][41]. One-, 3-, and 5-year success rates with the procedure are estimated to be around 62%, 50%, and, 32%, respectively, showing a decrease in response rate over time [37].…”

Section: Treatment Optionsmentioning

confidence: 99%

Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation

et al. 2019

View full text Add to dashboard Cite

Glaucoma is a chronic, debilitating disease and a leading cause of global blindness. Despite treatment efforts, 10% of patients demonstrate loss of vision. In the US, [ 80% of glaucoma cases are classified as open-angle glaucoma (OAG), with primary open-angle (POAG) being the most common. Although there has been tremendous innovation in the surgical treatment of glaucoma as of late, two clinical variants of OAG, normaltension glaucoma (NTG) and severe POAG, are especially challenging for providers because patients with access to care and excellent treatment options may progress despite achieving a ''target'' intraocular pressure value. Additionally, recent research has highlighted the importance of nocturnal IOP control in avoiding glaucomatous disease progression. There remains an unmet need for new treatment options that can effectively treat NTG and severe POAG patients, irrespective of baseline IOP, while overcoming adherence limitations of current pharmacotherapies, demonstrating a robust safety profile, and more effectively controlling nocturnal IOP.

show abstract

Section: Treatment Optionsmentioning

confidence: 99%

Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…SLT has a very short pulse duration (3 ns), which is shorter than the thermal relaxation time of melanin, allowing for selective photo thermolysis. Because SLT selectively targets the pigmented TM cells and has an energy level ˂ 1% of ALT, it is a gentle laser than ALT with no or minimal histologic scarring or coagulative damage to the TM, thus reducing collateral damage to surrounding tissues [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Selective Laser Trabeculoplasty among Ethiopian Glaucoma Patients

Soboka

Giorgis

Alemu

et al. 2020

Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Background. Selective laser trabeculoplasty (SLT) is a safe and effective treatment modality for lowering intraocular pressure (IOP). Purpose. To determine the efficacy and safety of SLT among Ethiopian patients with primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PXG), and ocular hypertension (OHT). Method. A prospective, nonrandomized interventional study was conducted at Menelik II Hospital, Ethiopia. Patients on antiglaucoma medication with uncontrolled IOP and those patients treated for the first time with 360 degrees of SLT were included. Success was defined as an IOP lowering of > 20% from baseline without repeat treatment. Result. A total of 95 eyes of 61 patients with a diagnosis of OAG and OHT were enrolled. The diagnosis was POAG in 55 (57.9%) eyes, PXG in 22 (23.2%) eyes, and OHT in 18 (18.9%) eyes. Seventy (73.7%) eyes were on medications, and 25 (26.3%) eyes were treated with laser as primary therapy. The mean (SD) baseline IOP and medication were 24.3 ± 2.5 mmHg and 1.29 ± 1.01, respectively. The one-year mean (SD) IOP reduction was 6.7 ± 4.2 mmHg and medication reduction was 0.26 ± 1.34. The overall IOP reduction at 12 months was 27.6%, and the success rate was 60%. The mean IOP (SD) reduction for patients who were treated for the first time with laser and on antiglaucoma medication was 6.5 ± 3.1 mmHg and 6.8 ± 2.8 mmHg, respectively. Post-SLT, patients experienced transient ocular pain, brow ache, headache, and/or blurring of vision in 31.6%, anterior chamber reaction in 36.8%, and IOP spike ≥ 6 mmHg in 11.6%. Conclusion. SLT is an effective and safe treatment modality for OHT, POAG, and PXG among Ethiopian patients either as a first-line treatment or as an adjunct to topical glaucoma treatment.

show abstract

“…413 Some studies suggest that SLT has greater success than ALT with repeated treatments, whereas others do not. 414 Studies report varying success rates with repeat SLT compared with initial SLT in retrospective studies. [415][416][417] The safety profile of SLT appears to be good, with only mild anterior chamber inflammation after treatment and less ocular discomfort compared with ALT.…”

Section: Selective Laser Trabeculoplastymentioning

confidence: 99%

Primary Open-Angle Glaucoma Preferred Practice Pattern®

Gedde¹,

et al. 2021

View full text Add to dashboard Cite

show abstract

Selective Laser Trabeculoplasty versus Argon Laser Trabeculoplasty in Glaucoma Patients Treated Previously with 360° Selective Laser Trabeculoplasty

Cited by 32 publications

References 19 publications

Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation

Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation

Efficacy and Safety of Selective Laser Trabeculoplasty among Ethiopian Glaucoma Patients

Primary Open-Angle Glaucoma Preferred Practice Pattern®

Contact Info

Product

Resources

About